Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMOJ7QA)

Drug Name

Mitemcinal fumarate Drug Info

Synonyms

(2S,4R,5R,8R,9S,10S,11R,12R)-5-ethyl-9-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-11-[(2S,3R,4S,6R)-3-hydroxy-6-methyl-4-[methyl(propan-2-yl)amino]oxan-2-yl]oxy-4-methoxy-2,4,8,10,12,14-hexamethyl-6,15-dioxabicyclo[10.2.1]pentadec-1(14)-ene-3,7-dione

Indication

Disease Entry	ICD 11	Status	REF
Pain	MG30-MG3Z	Phase 2	[1]

Cross-matching ID

PubChem CID: 11513721
CAS Number: CAS 154802-96-7
TTD Drug ID: DMOJ7QA

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Motilin receptor (MLNR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MOTILIN	DMVILAD	N. A.	N. A.	Phase 4	[3]
Camicinal	DMAKSMX	Delayed gastric emptying	DA41.00	Phase 2	[4]
RWJ-68023	DM4O07Q	Irritable bowel syndrome	DD91.0	Phase 1	[5]
KOS-2187	DM4953W	Gastroesophageal reflux disease	DA22.Z	Phase 1	[6]
DS-3801	DM6WN9X	Constipation	DD91.1	Phase 1	[7]
GSK-1322888	DMNYGB8	Gastroparesis	DA41.00	Phase 1	[8]
KW-5139	DMLOKXI	Pain	MG30-MG3Z	Discontinued in Phase 2	[9]
KC-11458	DMOITN2	Gastric motility disorder	DA21	Discontinued in Phase 2	[10]
SLV-305	DMBZM0D	Gastric motility disorder	DA21	Discontinued in Phase 2	[4]
SLV-311	DM5TJIY	Gastrointestinal disease	DE2Z	Discontinued in Phase 1	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Motilin receptor (MLNR)	TT953CX	MTLR_HUMAN	Agonist	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT00050882) Safety and Effectiveness of an Investigational Agent (GM-611) in Patients With Diabetic Gastroparesis. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of Roche (2009).
3	Discovery of a new class of macrocyclic antagonists to the human motilin receptor. J Med Chem. 2006 Nov 30;49(24):7190-7.
4	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 297).
5	Effects of a nonpeptide motilin receptor antagonist on proximal gastric motor function. Br J Clin Pharmacol. 2004 Apr;57(4):393-401.
6	Kosan Announces Selection of KOS-2187 As Motilide Clinical Candidate at World Congress of Gastroenterology Meeting. Kosan. 2006.
7	Clinical pipeline report, company report or official report of Daiichi Sankyo.
8	ClinicalTrials.gov (NCT01294566) FTIH to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Oral Doses of GSK1322888 in Healthy Caucasian and Japanese Volunteers. U.S. National Institutes of Health.
9	Stimulating action of KW-5139 (Leu13-motilin) on gastrointestinal motility in the rabbit. Br J Pharmacol. 1994 Jan;111(1):288-94.
10	Effect of the motilin agonist KC 11458 on gastric emptying in diabetic gastroparesis. Aliment Pharmacol Ther. 2004 Aug 1;20(3):333-8.
11	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017412)